NCT00969813

A Safety and Tolerability Study of CP-690,550 in Subjects With Hepatic Impairment and Normal Hepatic Function

A Phase 1, Non-Randomized, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CP-690,550 in Subjects With Hepatic Impairment and Normal Hepatic Function

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 18 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Accepted

Summary

This study is designed to evaluate how CP-690,550 is handled by the body in healthy volunteers who have mild and moderate hepatic impairment compared to healthy volunteers with normal hepatic function. This study will also evaluate the safety and tolerability of CP-690,550.

Conditions

• Hepatic Insufficiency

Interventions

Type	Name	Description
DRUG	CP-690,550	Single 10 mg dose of CP-690,550
DRUG	CP-690,550	Single 10 mg dose of CP-690,550
DRUG	CP-690,550	Single 10 mg dose of CP-690,550

Timeline

• Start date: 2009-11-01
• Primary completion: 2010-01-01
• Completion: 2010-01-01
• First posted: 2009-09-01
• Last updated: 2010-02-11

Locations

1 site across 1 country: United States